These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 8754326)

  • 1. [Cardiotoxic effect of the herec-TNF alpha preparation given intravenously to patients with advanced neoplasms].
    Muc M; Baranowski M; Braczkowski R; Zubelewicz B; Kozowicz A
    Przegl Lek; 1996; 53(2):78-82. PubMed ID: 8754326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
    Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil].
    Katsuramaki T; Furuhata T; Kimura Y; Yamaguchi K; Ohmura T; Hata F; Mukaiya M; Hirata K
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1801-4. PubMed ID: 12402433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible biological indicators of the response to recombinant tumour necrosis factor alpha in patients with advanced neoplasms.
    Braczkowski R; Zubelewicz B; Romanowski W; Lissoni P; Brivio F
    J Exp Clin Cancer Res; 1998 Sep; 17(3):349-54. PubMed ID: 9894774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
    Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
    Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
    Nagano H; Miyamoto A; Wada H; Ota H; Marubashi S; Takeda Y; Dono K; Umeshita K; Sakon M; Monden M
    Cancer; 2007 Dec; 110(11):2493-501. PubMed ID: 17941012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
    Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
    Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential phase II trials of fluorouracil and interferon beta ser with or without sargramostim in patients with advanced colorectal carcinoma.
    Wadler S; Haynes H; Rozenblit A; Hu X; Kaleya R; Wiernik PH
    Cancer J Sci Am; 1998; 4(5):331-7. PubMed ID: 9815298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
    Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
    Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
    Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
    J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
    Koizumi W; Kurihara M; Hasegawa K; Chonan A; Kubo Y; Maekawa R; Iwasaki R; Sasai T; Fukuyama Y; Ishikawa K; Miyoshi K; Yasutake K; Hayakawa M
    Oncol Rep; 2004 Sep; 12(3):557-61. PubMed ID: 15289837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study.
    Nakata B; Sowa M; Tsuji A; Kamano T; Sasaki K; Fukunaga Y; Takahashi M; Tsujitani S; Mikami Y; Mitachi Y; Nishimura S; Araki H; Yamamitsu S; Hirakawa K; Tominaga S; Shirasaka T; Inokuchi K
    J Exp Clin Cancer Res; 2007 Mar; 26(1):51-60. PubMed ID: 17550132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
    Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
    Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
    Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of advanced pancreatic cancer with interferon alpha, tumor necrosis factor and 5-fluorouracil (preliminary report].
    Muc M; Baranowski M; Braczkowski R
    Wiad Lek; 1995; 48(1-12):198-202. PubMed ID: 9638240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of intravenous treatment with tumor necrosis factor alpha in patients with advanced cancer--phase I clinical trials].
    Muc M; Baranowski M
    Przegl Lek; 1995; 52(10):496-8. PubMed ID: 8834840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292).
    Wadler S; Bajaj R; Neuberg D; Agarwal V; Haynes H; Benson AB
    Cancer J Sci Am; 1997; 3(5):284-8. PubMed ID: 9327152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient increase of plasma interleukin-6 after infusion of recombinant tumor necrosis factor alpha in advanced cancer patients.
    Zubelewicz B; Romanowski W; Braczkowska B; Lissoni P; Braczkowski R
    J Exp Clin Cancer Res; 1998 Dec; 17(4):449-52. PubMed ID: 10089067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.